
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is positioned favorably for growth due to its innovative dually derived chitosan (DDX) gene delivery platform, which facilitates localized delivery of gene therapies to mucosal tissues, addressing significant unmet medical needs in non-muscle invasive bladder cancer (NMIBC). The company has achieved a substantial increase in its clinical progression metrics, with detailimogene's six-month complete response (CR) rates aligning with leading assets in the field while benefiting from a superior non-viral profile, thus expanding potential market share, particularly in community practice settings. Furthermore, enGene's strategic focus on advancing its pipeline, alongside a notable increase in research and development expenditures reflecting its commitment to clinical advancements, supports a positive outlook for future revenue growth and market penetration.
Bears say
The ongoing LEGEND trial for detalimogene has shown disappointing performance, compounded by unexpected safety issues and changing regulatory requirements for non-muscle invasive bladder cancer (NMIBC). The introduction of TAR-200 as a competitive alternative presents additional challenges, notably due to its procedural burden and safety metrics, which could hinder enGene’s market penetration. Furthermore, the company is expected to face significant financial pressures, necessitating additional equity financing that may lead to further dilution for shareholders, thus negatively impacting the stock's outlook.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares